Fast Track Designation Granted for VMT01 for the Diagnosis & Treatment of MC1R-Positive Melanoma September 10, 2024
GI Innovation Announces New Clinical Trial Collaboration and Supply Agreement to Evaluate GI-102 + KEYTRUDA in Patients with IO-Resistant HCC, Melanoma, and RCC September 3, 2024
Ph 3 KEYNOTE-867 trial in NSCLC and KEYNOTE-630 Trial in cSCC to be discontinued based on DMC recommendations September 3, 2024
Ph 3 Trial of IO102-IO103 + KEYTRUDA as 1L Treatment in Advanced Melanoma to be continued without modifications based on DMC recommendations September 3, 2024
Ph 2 results from LTX-315 skin cancer (BCC) trial show an 86% overall reduction of tumor size, complete clearance in half of the patients August 22, 2024
Positive Topline Ph 2 Results Announced for mRNA Immunotherapy BNT111 in Patients with Advanced Melanoma August 6, 2024
FDA Accepts BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma July 30, 2024
Update Provided from iSCIB1+ Clinical Advisory Meeting to Strengthen Plans for Ph 2/3 Registration Clinical Trial July 27, 2024
BLA resubmitted to the FDA for cosibelimab for patients with metastatic or locally advanced cSCC not candidates for curative surgery or curative radiation July 9, 2024
SEACRAFT-2 Pivotal Ph 3 Trial of Naporafenib + Trametinib Initiated in Patients with NRAS-Mutant Melanoma June 25, 2024
3-Year Data For mRNA-4157 (V940) + KEYTRUDA Demonstrated Sustained Improvement in RFS & Distant MFS vs KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection June 11, 2024
Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Trial of RP1 + Nivolumab in Anti-PD1 Failed Melanoma Announced June 11, 2024
Ph 2/3 TEBE-AM trial converted into registrational Ph 3 trial of KIMMTRAK for previously treated advanced cutaneous melanoma June 4, 2024
Ph 3 KeyVibe-010 Trial of Vibostolimab + Pembrolizumab coformulation as Adjuvant Treatment for Resected High-Risk Melanoma unlikely to achieve a statistically significant RFS improvement May 15, 2024
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma March 26, 2024
NMPA grants Approval to Tunlametinib (HL-085) for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1 March 26, 2024
Patient Recruitment completed for the Ph 2a Trial of MaaT013 + Immune Checkpoint Inhibitors in Metastatic Melanoma March 12, 2024
FAILED TRIAL: Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma Announced March 12, 2024
Immunocore and BMS to evaluate IMC-F106C (PRAME HLA-A02) + Opdivo in registrational Ph 3 1L melanoma trial February 26, 2024
